TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

In order to participate, please register in advance  to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on Teva's website at:

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit .

Cautionary Note Regarding Forward-Looking Statements

This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our substantial indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2024, and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

IR Contacts Ran Meir+1 (267) 468-4475
  Yael Ashman+972 (3) 914 8262
  Sanjeev Sharma+1 (973) 658 2700 
Media Contacts Kelley Dougherty



Eden Klein
+1 (973) 832-2810



+972 (3) 906 2645


EN
30/09/2024

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The F...

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration1AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention ...

Si Yong Ng
  • Si Yong Ng

Teva - Earnings Flash - Q2 FY 2025 Results - Lucror Analytics

Teva has reported good Q2/25 numbers, with adjusted EBITDA rising y-o-y. While reported sales were broadly flat, they would have increased if adjusting for the disposal of the Japan business venture (BV). Cash generation improved. Reported net leverage was broadly flat q-o-q, while liquidity remained adequate. We anticipate decent H2/25 results, with continued top-line-supported growth in Austedo, Ajovy and Uzedy to offset headwinds from the Japan BV disposal. Profitability should benefit fr...

Josseline Jenssen ... (+2)
  • Josseline Jenssen
  • Si Yong Ng

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: GOL, Teva

Felix Fischer ... (+7)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
  • Trung Nguyen

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Trivium, Applus, Altice France (SFR), Casino Guichard-Perrachon, International Personal Finance, TeamSystem, Aston Martin, Virgin Media O2, Liberty Global, TalkTalk, Recordati, Tata Motors, Nexans, Italmatch Chemicals, Itelyum Group, Teva

 PRESS RELEASE

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth i...

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy.Q2 2025 shows 10th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local currencyterms (“LC“)excluding Japan BV revenues; United States segment +2%; Europe segment +3% in LC; International Markets segment -4% inLCand excluding Japan BV revenues. Innovative portfolio continu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch